Market Cap 31.41M
Revenue (ttm) 11.00M
Net Income (ttm) -69.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -634.36%
Debt to Equity Ratio 0.00
Volume 1,213,000
Avg Vol 1,721,520
Day's Range N/A - N/A
Shares Out 58.79M
Stochastic %K 4%
Beta 1.04
Analysts Sell
Price Target $10.00

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 0708
Fax: 858 558 0709
Address:
11085 Torreyana Road, San Diego, United States
shortkiller7
shortkiller7 Jan. 8 at 9:26 AM
$BCAB yesterday vWAP = $0.43, Convertible price $0.4085, convertible quantity 18,359,853 shares LOL but boom up! short go hell!!!!!!!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:04 AM
$BCAB Boom up!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:03 AM
$BCAB Merck is comming!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:03 AM
$BCAB Full buying! Anticipate JPM healthcare conference!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:03 AM
$BCAB After RS big deal is comming!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:02 AM
$BCAB Short go hell!!!!!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 4:57 AM
$BCAB Is BioAtla attending the JPM health conference 2026? If the partnership story is continuing, why don't they announce their attendance?
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 4:36 AM
$BCAB vWAP = $0.43, Convertible price $0.4085, convertible quantity 18,359,853 shares LOL
0 · Reply
shortkiller7
shortkiller7 Jan. 7 at 10:56 PM
$BCAB If the Press release & closing date in the PPA contract mean the same day (11/21), this should never be taken lightly. 1. 11/21 News 'closing' Key terms of the pre-paid advance include $7.5 million purchased at 95% of face value for $7.125 million gross proceeds received at closing. This advance accrues interest at 4% and may be repaid in cash or converted into common stock based on a conversion price equal to the lower of $1.39 or 95% of the lowest daily VWAP over trading day look back period. The trading day look back period will begin no earlier than November 18, 2025. 2. 11/24 PPA agreement 'Closing date' but in no event shall the Market Price be less than 20% of the Nasdaq official closing price immediately prior to the Closing Date (the “Floor Price”), and provided that for any date of Purchase Notice before November 28, 2025,
1 · Reply
shortkiller7
shortkiller7 Jan. 7 at 10:51 PM
$BCAB Bio, Day of Surging! BCAB Left Alone.
0 · Reply
Latest News on BCAB
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 6:51 PM EST - 7 weeks ago

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:43 AM EDT - 5 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 5:55 PM EDT - 8 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript


BioAtla to Participate in the Citizens Life Sciences Conference

Apr 30, 2025, 8:00 AM EDT - 9 months ago

BioAtla to Participate in the Citizens Life Sciences Conference


BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 6:18 PM EDT - 10 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript


BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 5:05 PM EDT - 10 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort


BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript


BioAtla: Numerous Catalysts Coming In Q4

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4


BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript


BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript


BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024


BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript


shortkiller7
shortkiller7 Jan. 8 at 9:26 AM
$BCAB yesterday vWAP = $0.43, Convertible price $0.4085, convertible quantity 18,359,853 shares LOL but boom up! short go hell!!!!!!!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:04 AM
$BCAB Boom up!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:03 AM
$BCAB Merck is comming!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:03 AM
$BCAB Full buying! Anticipate JPM healthcare conference!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:03 AM
$BCAB After RS big deal is comming!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 8:02 AM
$BCAB Short go hell!!!!!
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 4:57 AM
$BCAB Is BioAtla attending the JPM health conference 2026? If the partnership story is continuing, why don't they announce their attendance?
0 · Reply
shortkiller7
shortkiller7 Jan. 8 at 4:36 AM
$BCAB vWAP = $0.43, Convertible price $0.4085, convertible quantity 18,359,853 shares LOL
0 · Reply
shortkiller7
shortkiller7 Jan. 7 at 10:56 PM
$BCAB If the Press release & closing date in the PPA contract mean the same day (11/21), this should never be taken lightly. 1. 11/21 News 'closing' Key terms of the pre-paid advance include $7.5 million purchased at 95% of face value for $7.125 million gross proceeds received at closing. This advance accrues interest at 4% and may be repaid in cash or converted into common stock based on a conversion price equal to the lower of $1.39 or 95% of the lowest daily VWAP over trading day look back period. The trading day look back period will begin no earlier than November 18, 2025. 2. 11/24 PPA agreement 'Closing date' but in no event shall the Market Price be less than 20% of the Nasdaq official closing price immediately prior to the Closing Date (the “Floor Price”), and provided that for any date of Purchase Notice before November 28, 2025,
1 · Reply
shortkiller7
shortkiller7 Jan. 7 at 10:51 PM
$BCAB Bio, Day of Surging! BCAB Left Alone.
0 · Reply
shortkiller7
shortkiller7 Jan. 7 at 10:23 PM
$BCAB @BIOCARP's analysis has never been correct once. Floor price is 0.23.
0 · Reply
BIOCARP
BIOCARP Jan. 7 at 9:00 PM
1 · Reply
BIOCARP
BIOCARP Jan. 7 at 8:59 PM
0 · Reply
BIOCARP
BIOCARP Jan. 7 at 8:34 PM
0 · Reply
BIOCARP
BIOCARP Jan. 7 at 8:33 PM
$BCAB It looks like the beaIt looks like the bears are taking a breather from the technicals. There might be a rebound if we break out of the triangle I've outlined, projecting a move to $0.63. It's worth a shot.rs are taking a breather from the technicals. There might be a rebound if we break out of the triangle I've outlined, projecting a move to $0.63. It's worth a shot.
0 · Reply
BIOCARP
BIOCARP Jan. 7 at 6:52 PM
$BCAB Based on technical analysis, RSI, and momentum, a rebound to $0.60 is expected. We'll see how it plays out. The market capitalization is ridiculously low considering the amount of money it will have and everything the company owns.
0 · Reply
bcabing
bcabing Jan. 7 at 4:04 PM
$BCAB Amazing short for delisting & RS!
0 · Reply
BioMan122
BioMan122 Jan. 7 at 3:45 PM
$BCAB so weak
0 · Reply
shortkiller7
shortkiller7 Jan. 7 at 3:08 PM
$BCAB there is no buying for delisting risk & RS risk & cash burn risk.
1 · Reply
pakman197
pakman197 Jan. 7 at 2:55 PM
0 · Reply
shortkiller7
shortkiller7 Jan. 7 at 12:14 PM
0 · Reply
bcabing
bcabing Jan. 7 at 12:06 PM
$BCAB Does these mean the same closing date? & If so, is floor price decided based on 11/20 closing price? 1. 11/21 News 'closing' Key terms of the pre-paid advance include $7.5 million purchased at 95% of face value for $7.125 million gross proceeds received at closing. This advance accrues interest at 4% and may be repaid in cash or converted into common stock based on a conversion price equal to the lower of $1.39 or 95% of the lowest daily VWAP over trading day look back period. The trading day look back period will begin no earlier than November 18, 2025. 2. 11/24 PPA agreement 'Closing date' but in no event shall the Market Price be less than 20% of the Nasdaq official closing price immediately prior to the Closing Date (the “Floor Price”), and provided that for any date of Purchase Notice before November 28, 2025, the Market Price shall instead equal to 95% of the lowest daily VWAP during the shorter period commencing on November 18, 2025
0 · Reply